加载中
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
常规交易时段
US$34.215
−US$0.375 · -1.08%
盘中时间采用ET。市场数据可能有所延迟。
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
日内区间
当前US$34.215
52周区间
当前US$34.215
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
4
估值过高
情绪
59
多空交织
风险
27
中等风险
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
日内区间
当前US$34.215
52周区间
当前US$34.215
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 826万 USD | 2905.3万 USD | 3271.3万 USD | 3153万 USD | 5528.6万 USD |
| 销货成本 | 128.5万 USD | 91.1万 USD | 159.9万 USD | 303.4万 USD | 896.6万 USD |
| 毛利 | 697.5万 USD | 2814.2万 USD | 3111.4万 USD | 2849.6万 USD | 4632万 USD |
| 研究与开发 | 6.82亿 USD | 5.5亿 USD | 4.4亿 USD | 4.54亿 USD | 4.83亿 USD |
| 销售、一般及管理费用 | 6.1亿 USD | 5.91亿 USD | 4.16亿 USD | 3.83亿 USD | 7.75亿 USD |
| 营业费用 | 12.92亿 USD | 11.42亿 USD | 8.56亿 USD | 8.38亿 USD | 12.58亿 USD |
| 利息收入 | 1.78亿 USD | 2.58亿 USD | 1.46亿 USD | 3218.4万 USD | 36.9万 USD |
| 利息支出 | — | — | 3477.8万 USD | 2796.8万 USD | 704.1万 USD |
| 折旧和摊销 | 334.8万 USD | 1407.1万 USD | 2203.6万 USD | 1885.7万 USD | 593.2万 USD |
| 营业利润 | −12.85亿 USD | −11.14亿 USD | −8.25亿 USD | −8.09亿 USD | −12.12亿 USD |
| 净利润 | −3亿 USD | −1.72亿 USD | 43.49亿 USD | −10.09亿 USD | −8.45亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$46.75
上涨空间 36.64%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5.55亿0.02%2.3万亿 USD0.03%US$380.59-0.26%
Vanguard Morningstar Small-Cap ETFVB4.01亿0.21%1853亿 USD0.03%US$286.67-0.52%
Invesco S&P MidCap Momentum ETFXMMO2.46亿3.45%71.38亿 USD0.34%US$145.56-0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2.3亿0.50%447亿 USD0.05%US$337.31-1.05%
Vanguard Extended Market ETFVXF1.81亿0.19%954亿 USD0.05%US$231.69-0.78%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.43亿0.55%258.17亿 USD0.23%US$663.66-0.55%
iShares Biotechnology ETFIBB1.41亿1.31%108.2亿 USD0.44%US$201.63-1.29%
State Street SPDR S&P Biotech ETFXBI1.23亿1.25%103.03亿 USD0.35%US$148.45-1.95%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Momentum ETFXMMOVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR S&P MIDCAP 400 ETF TrustMDYiShares Biotechnology ETFIBBState Street SPDR S&P Biotech ETFXBIAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
